Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.63

€0.63

-4.980%
-0.033
-4.980%
€3.00
 
25.04.24 / Tradegate WKN: A2PCBS / Name: Gossamer Bio Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Gossamer Bio Inc. Stock

Heavy losses for Gossamer Bio Inc. today as the stock fell by -€0.033 (-4.980%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Gossamer Bio Inc. stock is not clear.
Based on the current price of 0.63 € the target price of 3 € shows a potential of 375.44% for Gossamer Bio Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Gossamer Bio Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Gossamer Bio Inc. in the next few years

Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-27

Gossamer Bio Inc., a company in the biotechnology industry, exhibits financials that raise both concerns and opportunities for investors. A quick glance at the company's financial statements shows a pattern of increasing losses and negative stockholder equity. However, diving deeper into the details may help uncover valuable insights that could shape investment decisions regarding this company.

Increased total assets: The company's total assets have been gradually increasing over the years, from $539.43 million in 2020 to $343.66 million in 2021 and $272.45 million in 2022. This growth may signify an expansion in the company's resources and investments.

Rising research and development (R&D) expenses: Gossamer Bio continues to allocate a significant portion of its resources to R&D, indicating a commitment to product innovation. R&D expenses increased from $160.85 million in 2020 to $170.27 million in 2021 and $170.92 million in 2022. This trend suggests that the company is focused on developing its product pipeline.